Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Omaveloxolone Tablets for Oral Suspension Versus Capsules in Healthy Adults
NCT07297199Phase 1Completed
- Sponsor
- Biogen
- Start
- Dec 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of omaveloxolone in Friedreich ataxia (FA) (2 arms), sponsored by Biogen. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity. Started Dec 2025; status: completed.
02
Drugs
omaveloxolone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT07297199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297199.